• SPX
  • $5,595.76
  • 0.75 %
  • $41.63
  • DJI
  • $41,096.77
  • 0.58 %
  • $235.06
  • N225
  • $36,581.76
  • -0.68 %
  • -$251.51
  • FTSE
  • $8,251.86
  • 0.13 %
  • $10.89
  • IXIC
  • $17,569.68
  • 1 %
  • $174.14
Telomir Pharmaceuticals, Inc. Common Stock (TELO) Stock Price, News & Analysis

Telomir Pharmaceuticals, Inc. Common Stock (TELO) Stock Price, News & Analysis

Currency in USD Disclaimer

$5.91

-$0.03

(-0.51%)

Day's range
$5.75
Day's range
$5.99
50-day range
$3.11
Day's range
$6.95
  • Country: US
  • ISIN: N/A
52 wk range
$3.11
Day's range
$20.72
  • CEO: Dr. Christopher C. Chapman Jr., M.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 157.49
  • Piotroski Score 2.00
  • Grade N/A
  • Symbol (TELO)
  • Company Telomir Pharmaceuticals, Inc. Common Stock
  • Price $5.91
  • Changes Percentage (-0.51%)
  • Change -$0.03
  • Day Low $5.75
  • Day High $5.99
  • Year High $20.72

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) N/A
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $0.00
  • Trailing P/E Ratio N/A
  • Forward P/E Ratio N/A
  • P/E Growth N/A
  • Net Income $-13,071,864

Income Statement

Quarterly

Annual

Latest News of TELO

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.